Childhood nearsightedness (or myopia) is rising at an alarming rate, and for many families, eyeglasses have become an almost inevitable part of growing up. Now, researchers at the National Eye Institute (NEI) are launching a major clinical trial to find out whether new treatments can slow the progression of childhood myopia before it leads to more serious vision problems later in life.
The study will compare three treatment approaches in children: specialized eyeglass lenses designed to slow eye growth, nightly atropine 0.05% eye drops, and a combination of both therapies. Researchers hope to determine which approach works best for children.
Myopia happens when the eye grows too long from front to back, causing faraway objects to look blurry. While glasses or contact lenses can correct that blurry vision, they can’t stop the eye from continuing to lengthen. The more severe the myopia becomes, the greater the risk of serious eye conditions later in life, including retinal detachment, glaucoma, cataracts, and myopic macular degeneration.
That’s why researchers aren’t just trying to help kids avoid stronger prescriptions every year. Their bigger goal is to keep myopia from becoming severe enough to threaten a child’s vision decades down the road.
RELATED: What to Know Before Enrolling Your Child in a Clinical Trial
Historically, Black children have developed myopia at lower rates than some Asian and white children, but that gap is closing. As kids spend more time on screens and less time outdoors, eye doctors are seeing myopia become increasingly common across all racial and ethnic groups. In other words: no child is immune, and scheduling regular eye exams is more important than ever.
The new NEI study is also notable because it includes a diverse group of children from across the United States rather than relying on research from other countries. That’s important because treatments don’t always work the same way in every population.
For example, an earlier trial found that very low-dose atropine eye drops (0.01%) did not slow myopia progression in American children. Researchers suggested one possible reason could be differences in how children from different racial and ethnic backgrounds respond to the medication, though more research is needed to understand why. Because Black children were included in that study, the findings are more representative of the U.S. population than many earlier international studies.
The new trial is testing a higher dose of atropine (0.05%), which has shown more promising results in previous research. Researchers hope it will provide a clearer answer about whether the treatment can help slow myopia in children living in the United States.
Even if your child already wears glasses, it’s worth asking their eye doctor whether their prescription is changing at an appropriate pace. Children whose myopia worsens every year may eventually become candidates for treatments that do more than just sharpen vision.
Parents can also help reduce risk by encouraging children to spend more time outdoors. Research suggests that regular outdoor activity may lower the chances of developing myopia or slow its progression, although it doesn’t replace medical treatment once myopia is established. Limiting prolonged screen time and taking breaks may also help support healthy vision.
RELATED: What Black Patients Should Know About Glaucoma Clinical Trials
The NEI trial represents an important step toward personalized treatment for childhood myopia. Rather than assuming one therapy works for every child, researchers hope to learn which treatments are most effective across diverse populations.
For Black families, that’s encouraging news. Clinical trials that include participants from different racial and ethnic backgrounds help ensure future recommendations are based on evidence that reflects the children most likely to receive these treatments.
As childhood myopia continues to rise, studying the disease helps ensure a sighted future. Not only will kids be able to see the board in school today, but they may have a lower risk of vision-threatening disease years down the road.
By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.
